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Current evidence supports the notion that environmental exposures are associated with DNA-methylation and
expression changes that can impact human health. Our objective was to conduct a systematic review of epidemiologic
studies evaluating the association between environmental chemicals with DNA methylation levels in adults. After
excluding arsenic, recently evaluated in a systematic review, we identified a total of 17 articles (6 on cadmium, 4 on
lead, 2 on mercury, 1 on nickel, 1 on antimony, 1 on tungsten, 5 on persistent organic pollutants and perfluorinated
compounds, 1 on bisphenol A, and 3 on polycyclic aromatic hydrocarbons). The selected articles reported quantitative
methods to determine DNA methylation including immunocolorimetric assays for total content of genomic DNA
methylation, and microarray technologies, methylation-specific quantitative PCR, Luminometric Methylation Assay (LUMA),
and bisulfite pyrosequencing for DNA methylation content of genomic sites such as gene promoters, LINE-1, Alu elements,
and others. Considering consistency, temporality, strength, dose-response relationship, and biological plausibility, we
concluded that the current evidence is not sufficient to provide inference because differences across studies and limited
samples sizes make it difficult to compare across studies and to evaluate sources of heterogeneity. Important questions for
future research include the need for larger and longitudinal studies, the validation of findings, and the systematic evaluation
of the dose-response relationships. Future studies should also consider the evaluation of epigenetic marks recently in the
research spotlight such as DNA hydroxymethylation and the role of underlying genetic variants.
Keywords: Systematic review, DNA methylation, Environmental chemicals, Cadmium, Lead, Mercury, Metals, Persistent
organic pollutants, Bisphenol A, Polycyclic aromatic hydrocarbonsReview
Introduction
Beyond lifestyle determinants, the role of environmental
chemicals as determinants of DNA methylation has
gained considerable attention. Changes in DNA methyla-
tion add biological plausibility to the increasingly recog-
nized contribution of environmental chemicals to disease
burden [1] as DNA methylation is involved in regulating
many cellular processes, including X-chromosome* Correspondence: maria.tellez@uv.es
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article, unless otherwise stated.inactivation, genomic imprinting, chromosome stability,
and gene transcription. Environmental chemicals can
interfere with the one-carbon and citric acid metabolism
pathways, resulting in anomalous DNA-methylation status
throughout the genome [2,3]. Environmental chemicals
can also directly interact with enzymes involved not only
in one-carbon metabolism and citric acid metabolism
pathways but also in histone modifications [4-6]. A sum-
mary of suggested mechanisms of action of environmental
chemicals on DNA methylation machinery is shown in
Figure 1. In turn, these epigenetic mechanisms may mod-
ify potential toxicity pathways specific to the environmen-
tal chemicals in the organism.
Environmental chemicals have been linked to aberrant
changes in epigenetic pathways both in experimental and
epidemiological studies. In animal studies, maternal dietCentral. This is an Open Access article distributed under the terms of the
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, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 Overview of possible mechanisms of action for environmental chemicals on DNA methylation based on reviews of experimental
studies [2,3,5,135,136]. Metals, POPs, and PAH increase reactive oxygen species (ROS) formation. Under chronic consumption of glutathione (GSH) for
conjugation with ROS, chemicals, and their metabolites, homocysteine is employed into GSH rather than methionine synthesis pathways, leading to a
reduced synthesis of S-adenosylmethionine (SAM, a substrate for DNA methyltransferases (DNMT) which catalyzes the addition of the methyl group onto
the 5-carbon cytosine (5C) to become 5-methylcytosine (5mC)). SAM depletion, thus, potentially inhibits DNA methylation and results in subsequent DNA
hypomethylation [2]. Exposures to specific environmental chemicals such as short-term cadmium, PAH, lead, and mercury exposures can directly
reduce the enzymatic activity and concentrations of DNMT [136]. In addition, oxidative stress is proposed to stimulate the alpha-ketoglutarate (α-KG)
production from isocitrate. α-KG activates ten-eleven translocation (TET) proteins that catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC),
5-formlycytosine (5fC), and 5-carboxycytosine (5caC) in the presence of cofactors, iron and oxygen. 5hmC, 5fC, and 5caC could act as an intermediate in
both passive and active DNA demethylation pathways [3,135] involving DNA repair enzymes like AID, APOEC, and TDG. Overall, it facilitates DNA
hypomethylation. Conversely, it has been suggested that long-term cadmium exposure induces compensatory DNMT overexpression [4] that could lead
to increased DNA methylation. On the other hand, environmental chemicals can modulate the enzymes involved in covalent modifications (acetylation
(Ac), methylation (Me)), phosphorylation (P) and ubiquitination (Ub)) at the histone tails that can interact with the DNA methylation or demethylation
machinery. Lead has been related with transcription-active histone modifications (associated to DNA hypomethylation), while methylmercury and nickel
have been related with transcription-repressive histone modifications (associated to DNA hypermethylation) [5,136]. Finally, while other environmental
toxicants have been related to DNA hypomethylation (BPA, PFCs) and hypermethylation (tungsten, antimony) in epidemiologic studies, their mechanism
of action in epigenetic regulation of gene transcription is unknown.
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methylation of specific genes, which resulted in perman-
ent phenotypic changes including body weight and blood
pressure levels [7,8]. In humans, populations exposed to
famine during the prenatal period showed increased
prevalence of cardiometabolic factors and ischemic heart
disease mortality [9], with evidence supporting a mediat-
ing role of epigenetic mechanisms in disease pathogenesis[10]. Deleterious effects of epigenetic changes are not re-
stricted to the prenatal period. Monozygotic twins experi-
enced an epigenetic drift in relation to one another with
advancing age, time shared together, and behavioral fac-
tors such as smoking [11]. There is, however, a need to
undertake a systematic appraisal of the epidemiologic evi-
dence evaluating the potential role of environmental che-
micals as determinants of DNA methylation in adults.
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synthesis of results from epidemiologic studies evaluating
the association of environmental chemicals including cad-
mium, lead, mercury, nickel, persistent organic pollutants
(POPs), bisphenol A (BPA), polycyclic aromatic hydrocar-
bons (PAHs), and phthalates, with DNA methylation levels
in adults. We did not include arsenic studies in our search
because there is a recently published systematic review
published by Bailey et al. [12]. Other environmental expo-
sures, which have been related to DNA methylation, such
as exposure to tobacco smoke [13-17] and air pollution
[18], are out of the focus of the present review, as tobacco
smoke and air pollution are mixtures of different types of
chemicals rather than individual groups of compounds.
Methods
Search strategy, study selection, and data abstraction
We searched PubMed for relevant studies published
through 10 April 2014 using the search strategy described
in Additional file 1: Table S1 (Supplemental Material). The
search strategy retrieved a total of 867 citations (including
duplicates). We included all articles assessing environmen-
tal chemical exposures using biomarkers. The search had
no language restrictions. We also included two relevant
studies published after 10 April 2014 and identified by
hand search [19,20]. Two investigators (A.R.H. and C.C.K.)
independently reviewed each of all the abstracts and se-
lected 32 papers applying the following study exclusion cri-
teria (Figure 2): a) no original research (that is, reviews,
editorials, non-research letters); b) no human study; c) no
DNA methylation outcomes; d) no environmental chem-
ical exposure levels measured in biological tissues (for ex-
ample, environmental measures such as water or air, or
distance from a source). In this systematic review, the focus
was on the role of environmental chemicals exposure in
DNA methylation changes in adults. Therefore, as a sec-
ond layer of exclusion, we additionally excluded one study
focusing on prepubescent girls [21], and five studies that
focused on the association of maternal exposure bio-
markers and DNA methylation in cord blood or the off-
spring and did not provide corresponding measures of
DNA methylation in the mothers [22-26]. We additionally,
excluded two studies with semi-quantitative assessment of
DNA methylation [27,28] as the comparison of results with
quantitative DNA methylation assessment methods is un-
clear. Any discrepancies were resolved by consensus, and if
necessary, a third reviewer was involved. A native speaker
reviewed the full text of any non-English article that could
not be included or excluded based on the initial abstract
review. We included in the final review 17 papers, some of
them measuring multiple environmental toxicants evalu-
ated in unique study populations [19,29,30] (Figure 2). Our
review identified no publications investigating the associ-
ation between phthalates and DNA methylation. Afterretrieval of articles from the search, the reference lists of se-
lected articles were checked for other potentially relevant ar-
ticles, identifying no additional studies. We collected the
following data for each study: first author, year of publica-
tion, study design, size and population characteristics, ex-
posure assessment and categories for comparison, DNA
methylation assessment and endpoint definition, measures
of association and 95% confidence interval (CI) or P values,
and statistical methods including DNA methylation raw data
processing methods. For studies modeling exposures both
as continuous and as categorical, we reported continuous
measures of association due to space constraints in the ta-
bles. However, we evaluated flexible dose-response relation-
ships when reported. For polychlorinated biphenyls (PCBs),
when multiple congeners were reported, we selected the
congener with the weakest, highest, and median association.
We also reported all the statistically significant POPs.
To assess study quality, we adapted the criteria used by
Longnecker et al. for observational studies (Supplemental
Material, Additional file 2: Table S2) [31]. We followed the
criteria proposed by the 2004 US Surgeon General Report
on the health consequences of smoking [32], which include
the evaluation of consistency, temporality, strength, dose-
response relationship, and biological plausibility including
confounding. As a result, the evidence for each environmen-
tal chemical and DNA methylation was classified into four
groups as modified from the Surgeon General Report [32]:
sufficient evidence, suggestive but not sufficient evidence, in-
sufficient evidence to infer a relationship, and suggestive of
no relationship. We organized the presentation of the results
by environmental chemical.
Current perspectives and results
Cadmium and DNA methylation Cadmium exposure
from tobacco smoke, air pollution, occupation, and diet
(leafy and root vegetables, grains, and offal) is widespread in
general populations [33]. In the US, cadmium exposure has
substantially decreased during the last decades, in part re-
lated to reductions in smoking [34]. Cadmium exposure,
however, remains an important concern, because even at
the currently reduced levels of exposure, cadmium has been
related to cardiovascular, bone, and kidney disease in studies
of the US National Health and Nutrition Examination Sur-
vey (NHANES) 1999 to 2008 data [35-41]. In epidemiologic
studies, cadmium concentrations in blood and urine are
established biomarkers of cadmium exposure and internal
dose [33,42]. Both biomarkers can reflect cumulative expos-
ure, although blood cadmium also reflects short-term fluctu-
ations in exposure [33,42]. Experimental ex vivo evidence
showed that cadmium was an effective, noncompetitive
inhibitor of M.SssI DNA-methyltransferase (DNMT) (a bac-
terial DNMT that recognizes the same sequence as mam-
malian’s DNMTs) [4]. In rat liver cells, short-term cadmium
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Figure 2 Flow diagram of the study selection process. Summary of inclusion and exclusion criteria used in this systematic review of studies
investigating the association between environmental chemicals and DNA methylation levels, 10 April 2014. *17 references include the following studies
with multiple environmental toxicants evaluated in unique study populations: Hanna et al. (2012) [29] examined in SMART population urine cadmium,
blood lead and mercury, and serum BPA. Tajuddin et al. (2013) [30] examined in EPICURO population toenail cadmium, nickel, and lead. Tellez-Plaza et al.
(2014) [19] examined in the SHS populations urine tungsten, antimony, and cadmium. Abbreviations: BPA, bisphenol A; PCF, perfluorinated compounds.
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longed exposure, however, resulted in global DNA hyperme-
thylation [4,43-45]. In general, most in vitro and in vivo
studies showed increased gene-specific DNA methylation
after exposure to cadmium [46-52].
We identified six publications investigating the association
between cadmium and DNA methylation (Table 1). These
studies were conducted in the US [19,29,53], Argentina [54],
Spain [30], and China [55]. Cadmium exposure was mea-
sured in urine only [19,29], blood only [53], both in urine
and blood [54,55], and in toenail [30]. Global DNA methyla-
tion was assessed by pyrosequencing of LINE-1 elements (a
surrogate marker of global DNA methylation) in threestudies [29,30,54] and by an ELISA-like method (measure-
ment of percent 5-methylcytocine [5-mC] in DNA sample)
in one study [19]. CpG site-specific DNA methylation was
measured in candidate genes by pyrosequencing in one
study [55] and in an exploratory genome-wide manner using
microarray technologies in two studies [53,54].
In general, studies mostly showed a trend towards positive
associations of cadmium exposure and DNA methylation.
In a study population from Argentina (N= 200), however,
blood cadmium was positively associated with DNA methy-
lation in LINE-1 elements, but the association with urine
cadmium was inverse [54]. Among five studies evaluating
global or candidate gene methylation, three studies reported
Table 1 Studies of cadmium exposure biomarkers and DNA methylation outcomes (6 studies available)
First author,
year
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PPP2R5B = 1.56 0.0060


























Odds ratio QC reported. Models adjusted
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AAS: atomic absorption spectometry; BEE: batch effects evaluation; BMI: body mass index; CC: case-control; CH: Cell heterogeneity; CI: confidence interval; CO: cohort; CS: cross-sectional; DNAm, DNA methylation; FDR: false discovery
rate; MCC: multiple comparison correction; NR: not reported; LOD: limit of detection; QC: quality control.
aSociodemographic data available in the article, not necessarily in the subsample without missing values in DNA methylation or exposures.
bSignificance was defined as a difference score > |13| (p < 0.05) and >10% absolute difference between the means for each group.
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mium biomarkers [19,54,55]. In US American Indians, the
multi-adjusted odds ratio of percent 5-mC comparing par-
ticipants with urine cadmium levels above and below
0.87 μg/g was 1.75 (95% CI 0.96, 3.20) [19]. In the Argentin-
ean population, the difference in percent DNA methylation
in LINE-1 elements per log-unit increase in urine cadmium
was −0.42% (95% CI −0.82, −0.025) [54]. In a population
from Southern China (N = 81) [55], the difference in average
percent methylation in RASAL1 and KLOTHO genes per
log-unit increase in urine cadmium was, respectively, 0.88%
(95% CI 0.57, 1.20) and 1.55% (95% CI 0.75, 2.35). Both
epigenome-wide association studies [29,53] evaluated gen-
eral patterns in the association of DNA methylation in spe-
cific CpG sites and cadmium biomarkers in CpG sites with
an effect size considered relevant, consistently finding a
trend towards increased methylation with elevated cadmium
exposure. In the Study of Metals and Assisted Reproductive
Technologies (SMART) study, conducted in US women
undergoing ovarian stimulation [29], no sites were consid-
ered significant. In the CEHI study, conducted in US
mother-newborn pairs, percent increase in DNA methyla-
tion in the top five associated CpG sites ranged from 44% to
79% [53]. None of the genome-wide studies reported statisti-
cally significant regions after controlling for a false discovery
rate, although the study sample sizes were relatively small
[29,53]. Confounding by sex, age, and smoking status was
generally addressed, with exceptions [29]. Only two studies
[19,30] addressed the potential confounding effect of tissue
cell heterogeneity.
Lead and DNA methylation Lead in the environment
has decreased over the last decades when regulations ban-
ning the use of lead in gasoline, paint, and solders were
implemented [56,57]. The general population is exposed
through ambient air, alcohol consumption, and tobacco
smoke [58,59]. Patella and tibia lead are biomarkers of cu-
mulative lead exposure and body burden, while blood lead
is a biomarker of recent exposure including endogenous
exposure from bone [60]. Patella lead is biologically more
active than tibia lead [61], having a role in internal ex-
posure dose from redistribution of accumulated lead in
the body. Studies have shown associations between
low-exposure to lead and increased risk of neurocogni-
tive outcomes, high blood pressure, chronic kidney dis-
ease, hyperuricemia, gout, cardiovascular disease, cancer,
and other health effects [60,62,63]. In in vivo and in vitro
studies, lead exposure was associated with changes in
DNA methylation and expression of specific genes
[64-67], although experimental studies evaluating the
molecular mechanisms of lead-induced changes in DNA
methylation are needed.
We identified four publications investigating the asso-
ciation between lead and DNA methylation (Table 2).These studies were conducted in the US [29,68], China
[69], and Spain [30]. Lead exposure was measured in
blood [29,68,69], patella and tibia [68], or toenail [30].
Global DNA methylation was assessed by quantitative
pyrosequencing of LINE-1 or Alu elements (Alu is an-
other surrogate marker for global DNA methylation) in
three studies [29,30,68] and by methylation specific real-
time PCR in one study [69]. CpG site-specific DNA
methylation was measured in an exploratory genome-wide
manner using microarray technologies in one study [29],
with validation of significant regions by quantitative
pyrosequencing.
In general, all the studies reported a trend towards inverse
associations of lead exposure and global DNA methylation.
Two studies reported statistically significant associations
of DNA methylation with lead biomarkers [19,55]. In a
Chinese population (N = 110), participants showed 86.3%,
78.6%, and 73.9% average LINE-1 methylation in blood lead
groups including <100, 100 to 200, and >200 μg/L, respect-
ively (P trend <0.001). In 678 men from the US Normative
Aging Study, the absolute difference in average LINE-1
methylation percentage was −0.25% (95% CI −0.44, −0.05)
per an interquartile range change (19 μg/g) in patella lead
concentrations [68]. Blood and tibia lead biomarkers, how-
ever, did not show statistically significant associations with
LINE-1 methylation in this study population, although the
direction of the association was similar as compared to pa-
tella. The authors interpreted that the redistribution of ac-
cumulated lead from bone over time is associated with
DNA methylation in circulating leukocytes. In the only
epigenome-wide association study (N = 24) [53], a CpG site
in the COL1A2 gene showed decreased DNA methylation
with elevated blood lead exposure under the established
significance threshold. In pyrosequencing validation,
this site showed a 38% decrease in average percent methy-
lation (P value = 0.004) comparing individuals above and
below 0.73 μg/dL of blood lead concentrations. Among
CpG sites with an effect size considered relevant by the
authors, a general trend towards hypomethylation with in-
creasing blood lead levels was observed. There were not
reported statistically significant regions after controlling
for a false discovery rate [29]. Two (out of four) studies ad-
dressed potential confounding by sex, age, smoking status,
and tissue cell heterogeneity in DNA methylation status
[30,68]. While one of the studies was a cohort study with
repeated measurements of lead biomarkers and DNA
methylation [68], all the studies reported cross-sectional
associations.
Mercury and other metals and DNA methylation
Mercury is a highly reactive metal with unknown
physiological activity, which is persistent in the food
chain [70]. While the main source of inorganic mercury
is occupation (dentistry, mining, artisans manipulating
Table 2 Studies of lead exposure biomarkers and DNA methylation outcomes (4 studies available)
First author,
year
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38% decrease in
mean DNA m














659 89 66 Toenail by ICPMS Per 1 μg/g
increase
Granulocyte DNA Average %
methylation
Difference QC reported. CH addressed.
Adjusted for age, sex, study








110 91 mean = 39.45
(range 20-55)
Blood by AAS Peripheral leukocytes Average %
methylation
P <0.001 No QC reported. CH addressed
and adjustments not reported.










679 100 72.4 Buffy coat Average %
methylation
Difference QC reported. Models










LINE-1 −0.07 −0.29, 0.14




LINE-1 −0.25 −0.44, –0.05




LINE-1 0.04 −0.10, 0.19
Alu 0.03 −0.05, 0.10
AAS, atomic absorption spectrometry; BEE: batch effects evaluation; CH: Cell heterogeneity; DNAm, DNA methylation; IQR, interquartile range; LOD: limit of detection; MCC: multiple comparison correction; NR: not reported;
QC: quality control.
aSociodemographic data available in the article, not necessarily in the subsample without missing values in DNA methylation or exposures.
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the general population is mainly exposed to organic
mercury through consumption of fish (specially large
predatory fish) and in a lesser degree shellfish and other
marine animals [70]. Blood and hair mercury reflects
exposure to methylmercury. Urine mercury, however,
mainly reflects exposure to inorganic mercury [70].
Methylmercury is especially toxic for the neurologic
system, especially during infancy [71]. Both methylmer-
cury and inorganic mercury have immunotoxic effects,
although the immunotoxicity is higher for inorganic
mercury [71]. Other mercury-related health outcomes
include cardiovascular disease, cancer, alterations of the
reproductive system, and kidney disease [71-74]. There
is evidence from experimental studies that mercury can
change DNA methylation patterns. In rat embryonic
neural stem cells and prenatally exposed adult rats,
methylmercury reduced neural cell proliferation and
was associated with global DNA hypomethylation [75].
In mouse stem cells, mercury exposure induced aberrant
DNA methylation at specific gene loci [76]. The molecular
mechanisms for potential epigenetic effects of mercury,
however, are unknown.
Other nonessential metals are also of concern because
they have been related to diverse health outcome in human
studies. Tungsten has been related to cancer mortality
[77], lung cancer, respiratory alterations, electrocardiograph
abnormalities, and sudden death [78], and with prevalent
cardiovascular disease and peripheral arterial disease [38,79].
Antimony was associated with peripheral arterial disease
[38]. Nickel is an established carcinogen in occupational set-
tings (respiratory cancers), especially insoluble nickel subsul-
fide and nickel oxide [80]. Other chronic health effects
associated to nickel include rhinitis, sinusitis, nasal septum
perforations, asthma, skin allergies, and reproductive effects
[80]. However, experimental evidence indicating a potential
role in altering DNA methylation for these metals is scarce,
except for nickel. In vitro studies treatment with nickel re-
sulted in both promoter hypermethylation and increased
global DNA methylation [81,82]. Nickel may also influence
DNA methylation by deregulating epigenetic enzymes in-
volved in post-translational histone modifications [83,84].
For mercury, we identified two publications investigating
the association between mercury and DNA methylation
(Table 3). Both studies were conducted in the USA [29,85].
Mercury exposure was measured in blood [29] or urine and
hair [85]. For other metals, we only identified one publica-
tion investigating the association of DNA methylation with
toenail nickel in a population from Spain [30] and urine
tungsten and antimony in US American Indians [19].
Among all the retrieved studies evaluating mercury and
other metals, global DNA methylation was assessed by
pyrosequencing of LINE-1 elements in three studies
[29,30,85] and by and ELISA-like method in one study[19]. Site-specific DNA methylation was measured in
candidate genes by pyrosequencing in one study [85]
and in an exploratory genome-wide manner using micro-
array technologies in one study [29]. In 659 participants
from the Spanish Bladder Cancer Study (EPICURO) [55],
the difference in average percent methylation in LINE-1
elements per 1 μg/g increase in toenail nickel was 0.02%
(95% CI 0.005, 0.03). In the only study reporting both
cross-sectional and prospective associations, conducted in
US American Indians [19], the odds ratio of global DNA
methylation after 10 years of follow-up was 2.15 (95% CI
1.15, 4.01) comparing participants with baseline urine
antimony levels above and below 0.27 μg/g. The cross-
sectional association, however, was not statistically sig-
nificant [19]. In one epigenome-wide association study
in the SMART study population (N = 43) [53], only two
CpG sites in the GSTM1 gene showed increased DNA
methylation with elevated blood mercury exposure under
the established significance threshold of minimum abso-
lute change of 10% and a P value <0.05. In pyrosequencing
validation, CpG sites in this gene showed a 39% increase
in average % methylation (P value = 0.04) comparing indi-
viduals above and below 2.88 μg/L of blood mercury
concentrations. In this study, no statistically significant
positions were reported after controlling for a false dis-
covery rate [29]. The nickel, antimony, and tungsten
[19,30], but not mercury [29,85], studies reported fully
adjusted models including sex, age, and smoking status.
For mercury, since the major source of exposure in
humans is methylmercury from seafood consumption [86],
adjustments for nutrients (for example, selenium, magne-
sium, n-3 fatty acids), lifestyle (seafood as a proxy for
healthy diet), and other toxicants (POPs) in seafood should
be considered. Only nickel, antimony, and tungsten studies
[19,30] addressed the potential confounding effect of tissue
cell heterogeneity.
Persistent organic pollutants and other endocrine
disruptors and DNA methylation POPs are industrial
chemicals that persist in the environment for decades
even after production has been stopped [87]. The most
well known are dioxins, PCBs, and polybrominated diphe-
nyl ethers (PBDEs). Human exposure begins prenatally as
many POPs can cross the placenta [88]. After birth, expos-
ure occurs through breast milk [88] and also through in-
halation (dust), ingestion (dairy and animal products), and
skin contact [88,89]. POPs are lipophilic and accumulate
in the adipose tissue. The potential effects of POPs include
skin rashes to endocrine disruption, developmental delays,
metabolic syndrome and diabetes, and cancer, depending
on the type of compound and exposure [88].
Perfluorinated compounds (PFC) including perfluoroocta-
noic acid (PFOA) and perfluorooctanesulfonic acid (PFOS)
are fluorocarbons with at least one additional atom or
Table 3 Studies of mercury and other non-essential metals exposure biomarkers and DNA methylation outcomes (4 studies available)
First author,
year
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Table 3 Studies of mercury and other non-essential metals exposure biomarkers and DNA methylation outcomes (4 studies available) (Continued)
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BEE: batch effects evaluation; BMI: body mass index; CDT, Comparative Toxicogenomics Database; CC: case-control; CH: Cell heterogeneity; CI: confidence interval; CO: cohort; CS: cross-sectional; NR: not reported LOD: limit of detection;
QC: quality control.
aSociodemographic data available in the article, not necessarily in the subsample without missing values in DNA methylation or exposures.
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list of POPs regulated by The Stockholm Convention
[88]. For consistency with The Stockholm Convention
and as previously done in other systematic reviews [90],
we included PFCs in our search strategy for POPs.
Drinking water is the primary route of PFCs exposure
in some populations [91], but exposure sources are not
well understood. While PFCs are persistent in the en-
vironment and in the body (half-life in humans is 3 to 5
years depending on the compound), they are not me-
tabolized in humans and they are not lipophilic [91].
Animal data indicate that PFCs can cause several types
of tumors and neonatal death and may have toxic ef-
fects on the immune, liver, and endocrine systems. Data
on the human health effects include reported positive
associations with cholesterol levels, hepatic enzymes,
and adverse reproductive outcomes [91].
BPA is a compound with a shorter half-life compared to
POPs, but it is frequently grouped together with POPs
given its ubiquity and endocrine disruptor functions [88].
While humans are exposed through the placenta and in-
gestion (canned food), BPA is also present in dust and am-
bient air [88,92].
There are some studies evaluating the effect of POPs and
other endocrine disruptors on DNA methylation in experi-
mental settings. Exposure to dichlorodiphenyltrichloroeth-
ane (DDT) induced hypomethylation of CpG islands in Sst,
Gal, Arf1, Ttr, Msx1, and Grifin genes in the hypothalamus
of young male rats [93]. Rats treated in utero and postnatally
with organochlorine pesticides and PCBs also showed de-
creased methylation of CpG sites in the promoter of the
tumor suppressor gene p16 (INK4a) compared to controls
[94]. Perfluorooctanoic acid induced gene promoter hyper-
methylation of GSTP1 in human liver L02 cells [95]. Mater-
nal BPA exposure disrupted genomic imprinting in the
mouse embryos and placenta [96]. In rats, maternal expos-
ure to BPA modified methylation of the metastable loci Avy
and CapbIAP [97].
We identified four epidemiologic studies investigating the
association between POPs [20,98-100], and one publication
investigating PFCs [101] and BPA [29], respectively, with
DNA methylation in adults (Table 4). These studies were
conducted in the USA [29,101], South Korea [98], Sweden
[99], Denmark [100], and Japan [20]. In studies assessing
POPs, exposure was measured in plasma [100] or serum
[20,98,99]. BPA was measured in serum [29] and PFCs were
measured in blood [101]. Global DNA methylation was
assessed by quantitative pyrosequencing of LINE-1 or
Alu elements in four studies [29,98,100,101] and by
Luminometric Methylation Assay (LUMA) in two studies
[20,99]. CpG site-specific DNA methylation was measured
in an exploratory genome-wide manner using microarray
technologies in one study [29]. For most POPs, studies
evaluating DNA methylation globally showed a trendtowards hypomethylation with increasing levels of ex-
posure [20,98,100]. In studies measuring DNA methylation
in LINE-1 elements, no statistically significant association
was observed. The two studies measuring DNA methyla-
tion in Alu elements [98,100] showed consistent statisti-
cally significant inverse associations with oxychlordane,
p,p′-DDE and DDT. Increasing PCB183, heptachlor ep-
oxide, trans-nonachlordane, and PBDE47 in a study popu-
lation from Korea (N = 86) and PCB 156, 99, and 105,
β-HCH, α-chlordane, mirex, sum of PCBs, and sum of
POPs in a study population from Denmark (N = 70) was
significantly associated with lower DNA methylation in
Alu elements. Consistently, in a population of Japanese
women (N = 399), serum POPs were inversely associated
with the global DNA methylation level measured by
LUMA [20]. In an elder population from Sweden (N = 519)
[99], however, increasing total and non-ortho toxic equiva-
lency (TEQ) levels, PCB126, and p,p′-DDE concentrations
was significantly associated with increasing global DNA
methylation levels also measured by LUMA (P < 0.05) [99].
For PFCs, in a study population from the US (N = 671)
[101], a 12 ng/mL increase in PFOS levels was associated a
difference of 20% (95% CI 0.09 to 0.32) in average 5-mC
levels. Other PFCs did not show statistically significant as-
sociations. In one epigenome-wide association study in the
SMART study population (N = 35) [29], only one CpG site
in the TSP50 gene promoter showed increased DNA
methylation with elevated BPA exposure under the estab-
lished significance threshold of minimum absolute change
of 10% by BPA levels and a P value <0.05. In pyrosequenc-
ing validation, a region in this gene showed a 26% decrease
in average percent methylation (P value = 0.005) comparing
individuals above and below 2.39 μg/L of serum unconju-
gated BPA concentrations. In this study, no statistically sig-
nificant regions were reported after controlling for a false
discovery rate [29].
All studies tested at least five POPs, but only one study
[100] reported addressing multiple testing due to the
elevated number of compounds. Most studies addressed
potential confounding by sex, age, and smoking status
[20,98,99,101]. One study did not adjust for sex, although
the proportion of women was low [100]. One study pre-
sented unadjusted results [29]. POPs are highly lipophilic
and their serum concentrations are closely related to
serum lipid levels. Therefore, it is common practice to cor-
rect POP levels by lipid levels (that is, divide POP concen-
trations by total lipid concentrations). Alternatively, some
authors argue that lipid correction may be problematic
under certain assumptions [102]. In addition to lipid
correction, it is advisable to conduct sensitivity analyses
to evaluate robustness of findings using different approaches
of handling lipid adjustment, such as conducting separate
adjustment for total lipid levels with lipid-uncorrected POPs
in regression settings. All retrieved studies evaluating POPs
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CH assessment NR.
Models adjusted for
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LINE-1 PCB 118 .73 P = 0.12
PCB 128 .01 P = 0.99
PCB 156, 170 .48 P = 0.26 and 0.15
Alu PCB 156 .66 P < 0.01
PCB 52 .12 P = 0.36
PCB 99, 105 .51 P < 0.01 both
p,p’-DDT .26 P = 0.01
p,p’-DDE .38 P = 0.01
β-HCH .48 <0.01
Oxychlordane .32 <0.01
α-Chlordane .75 P = 0.05
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trans-Nonachlor, p,p’-DDE, p,p’-





LINE-1 PCB 157 .14 p ≥ 0.05
PCB 146 .02 p ≥ 0.05
PCB 105, 118, 156,
172, 180































Table 4 Studies of persistent organic pollutants (POPs) and other endocrine disruptors biomarkers and DNA methylation outcomes (6 studies available)
(Continued)
Alu PCB 183 –0.23 p < 0.05
PCB 167 –0.05 p ≥ 0.05
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PCB 169 −3.27 −6.92, 0.37
PCB 206 −0.16 −3.71, 3.38
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PCB 17, 28, 52/69, 48/47, 74,
66, 90/101, 99, 118, 114, 105,
146, 153, 164/163, 138, 128/
162, 167, 156, 182/187, 183,
177, 180, 170, 189, 202, 198/
199, 196, 203, 194, 208, 206







PCB196 −0.009 −0.38, 0.36
PCB74 −0.64 −1.08, −0.20
PCB28 and 66 −0.23 −0.59, 0.12
PCB17 −0.43 −0.78, −0.08
PCB52/69 −0.33 −0.67, −0.0007
PCB114 −0.46 −0.88, −0.05
PCB183 −0.45 −0.82, −0.07
p,p’-DDE, −0.77 −1.12, −0.42
o,p’-DDT, −0.75 −1.11, −0.40
p,p’-DDT , −0.83 −1.17, −0.49
trans-Nonachlor, −0.44 −0.84, −0.04










Table 4 Studies of persistent organic pollutants (POPs) and other endocrine disruptors biomarkers and DNA methylation outcomes (6 studies available)
(Continued)
β-HCH, −0.73 −0.79, −0.35
HCB, −0.41 −0.79, −0.03












Blood by HPLC separation
























PFOA 106 ng/mL −0.041 −0.098, 0.016
PFOS 12 ng/mL 0.204 0.090, 0.318
PFNA 0.8 ng/mL 0.064 −0.030, 0.158

























Unconjugated BPA by HPLC


























CH: cell heterogeneity; BDE, polybrominated diphenyl ether; BEE: batch effect evaluation; BMI: body mass index; CDT, Comparative Toxicogenomics Database; CC: case-control; CI: confidence interval; CO: cohort; CS: cross-sectional;
DNAm: DNA methylation; DDT, dichlorodiphenyl trichloroethane; DDE, dichlorodiphenyldichloroethylene; GC: gas chromatography; HPLC: high-performance liquid chromatography; HRGC-HRMS: high-resolution chromatography coupled
to high-resolution mass spectometry; HRMS: high resolution mass spectrometry; IQR: interquartile range; ITMS: isotope-dilution tandem mass spectrometry; LOD: limit of detection; LUMA: Luminometric Methylation Assay; MCC: multiple
comparisons correction; NR: not reported; PBDEs, polybrominated diphenyl ether; QC: quality control.
aSociodemographic data available in the article, not necessarily in the subsample without missing values in DNA methylation or exposures.
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Both standardization of summary POP measurements (TEQ
versus measured values or sum of POPs functional sub-
groups) and adjustment for lipid levels are ongoing
challenges that require consensus in order to facilitate
data comparison and meta-analysis. No study reported
evaluation of the potential confounding effect of tissue
cell heterogeneity.
Polycyclic aromated hydrocarbons and DNA
methylation PAHs are widespread environmental con-
taminants from incomplete combustion of organic mate-
rials such as fossil fuels, which are comprised of two or
more fused benzene rings arranged in various configura-
tions [103]. PAH metabolites in human urine, including
1-hydroxypyrene (1-OHP), 1-hydroxypyrene-O-glucuro-
nide, 3-hydroxybenzo[a]pyrene, 7,8,9,10-tetrahydroxy-7,8,9,
10-tetrahydrobenzo[a]pyrene, and a other hydroxylated
PAHs, can be used as biomarkers of internal dose to as-
sess recent exposure to PAHs [104]. Development of
biomarkers of exposure to PAHs and related compounds
includes detection of protein and DNA adducts, which
can be interpreted as indicators of effective dose [105].
The occurrence of PAHs in ambient air, food, drinking
water, tobacco smoke, automobile exhausts, dust, and con-
taminated air from occupational settings [106,107] is an
increasing concern for general populations given their
carcinogenicity and other reported potential health ef-
fects including allergy, asthma, cardiovascular, and re-
spiratory diseases [108]. The causative mechanisms of
PAH-related health effects on the molecular level are not
completely understood, and epigenetic mechanisms may
be involved. Benzo[a]pyrene (BaP) has been reported to
disrupt DNA methylation patterns in experimental models
[109,110]. In breast cancer cell lines, BaP treatment was
related to hypomethylation events at a number of repeat
elements [109]. BaP induced a 12% decrease in total 5-mC
content of cellular DNA of BALB/3 T3 mouse cells [110].
BaP exposure to zebrafish embryos significantly decreased
global DNA methylation by 44.8% [111]. Binding of BaP
adducts to DNA decreased methylation by reducing
binding and activity of DNMTs [112,113]. Interestingly,
experimental evidence suggests that PAH-DNA adduct
formation may preferentially target methylated genomic
regions [114-117] that may interfere their DNA methy-
lation status. As a result, the interpretation of BPDE-
adducts as indicators of effective dose in studies of DNA
methylation is not clear.
We identified three publications investigating the asso-
ciation between PAHs and DNA methylation (Table 5).
These studies were conducted in Mexico [118], Poland
[119], and China [120]. PAH exposure was measured
in urine as 1-hydroxypryene [118,120] or 1-pyrenol
[119] and in peripheral blood leukocytes as anti-B[a]PDE-DNA adducts [119]. Global DNA methylation
was assessed by quantitative pyrosequencing of LINE-1
and Alu elements in two studies [118,119]. CpG site-
specific DNA methylation was measured in candidate
genes by quantitative pyrosequencing in two studies
[118,119] and by methylation-specific quantitative PCR in
one study [120]. In the Polish study population (N = 92)
[119], increasing levels of blood and urine exposure bio-
markers were associated with increasing DNA methylation
in LINE-1 and Alu elements (all P values <0.004). In
contrast, in the Mexican study population (N = 39),
urine 1-hydroxypyrene was inversely associated with
LINE-1 and Alu elements [118]. The associations, how-
ever, were not statistically significant. The two studies
evaluating DNA methylation in candidate regions by
quantitative pyrosequencing showed consistent direc-
tions in the associations with increasing exposure bio-
markers levels in genes p53 and IL-6 [118,119]. The
associations, however, were statistically significant only
in the Polish study (absolute difference in average per-
cent 5-mC per unit increase in urine exposure bio-
marker was −1.58% (P < 0.001) in p53 and 1.06% (P =
0.012) IL-6 genes) [119]. In the Mexican population, the
difference in average percent 5-mC was −1.57% (95% CI
−2.9%, −0.23%) for a genomic region in IL-12 [118]. In
the Chinese study population (N = 128), the p16INK4α pro-
moter methylation measured by methylation-specific
quantitative PCR [120] showed a positive correlation with
urine 1-hydroxypyrene (Spearman r = 0.45, P < 0.001),
which was not consistent with the nonsignificant results
from the Polish study [119]. Only one study addressed
potential confounding including sex, age, and smoking
status [118]. No study reported evaluation of potential
confounding effect of tissue cell heterogeneity.General discussion and needs for future epidemiologic
research
Epidemiologic evidence from distinct study populations
suggests a trend for an association between increasing
cadmium exposure with increased DNA methylation and
a trend for an association between increasing lead and
POP exposures with decreased DNA methylation, al-
though additional studies are needed to confirm those
trends. For other environmental chemicals, the low
number of studies did not allow to recognize patterns
in their associations with measures of DNA methylation.
The epidemiologic associations were mostly in agreement
with experimental evidence, although additional work is
needed to better understand the relevance of the dose
levels and routes of administration used in experimental
studies in the context of human exposure. While the lim-
ited number of studies and the heterogeneity in DNA
methylation markers limit the conclusion of this review,
Table 5 Studies of PAH exposure biomarkers and DNA methylation outcomes (3 studies available)
First author,
year




























Urine Per μg/g increase Peripheral leukocytes Average %
methylation
QC or CH assessment NR.
Models adjusted for smoking
status, usual alcohol drinking,
current medication, age, and










Interleukin 12 −1.57 −2.9, −0.23
p53 −2.7 −5.46, 0.06
TNF-α −3.9 −8.28, 0.48
IFN-γ −0.43 −16.45, 15.59
IL-6 0.22 −9.19, 9.63
Global
LINE-1 −0.49 −4.74, 3.76
Alu −0.55 −1.25, 0.16
Pavanello,
2009 [119]
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p53 −1.58 P < 0.001
p16 −0.01 P = 0.736
HIC1 −0.57 P = 0.059
IL-6 1.06 P = 0.012
Global 0.72 P = 0.01
LINE-1 0.13 P = 0.004
Alu
Anti-BPDE–DNA by HPLC-





p53 −1.04 P < 0.001
p16 −0.02 P = 0.314
HIC1 −0.31 P = 0.142
IL-6 0.57 P = 0.043
Global
LINE-1 0.63 P < 0.001










Table 5 Studies of PAH exposure biomarkers and DNA methylation outcomes (3 studies available) (Continued)
Yang, 2012
[120]
CS Anshan City, Liaoning,
China






QC or CH NR. Unadjusted
for potential confounders.
1-Hydroxypyrene Specific by methylation
specific quantitative PCR
(Overall mean=6.56) p16INK4α r spearman
= 0.450
<0.001
AAS, atomic absorption spectrometry; BaP, benzo[a]pyrene; CH: cell heterogeneity; HPLC, high-performance liquid chromatography; HPLC-F, high-performance liquid chromatography–fluorescence; IQR, interquartile range; LOD, limit of
detection; NR: not reported; QC: quality control.
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environmental exposures in modulating the epigenome.
A limitation of the review was the substantial heterogen-
eity in the assessment methods of DNA methylation, espe-
cially for studies reporting global DNA methylation, which
challenged the comparability across studies. For instance,
LINE-1 and Alu repetitive elements have been classically
used as a surrogate marker for global DNA methylation
because they are abundant, hypermethylated, regions in
the genome (more than one third of DNA methylation in
these repetitive elements) [121]. LINE-1 and Alu elements,
however, could be regulated by specific mechanisms and
respond specifically to cellular stressors [122]. Other stud-
ies assessed DNA methylation globally by estimating the
percentage of methylated DNA over the total number of
genomic cytosines [19] or the LUMA methylation index
[20,99] that goes from 0 (fully methylated DNA) to 1 (fully
demethylated DNA). Among studies reporting absolutes
differences in global DNA methylation, the strength of the
statistically significant associations ranged between a dif-
ference (absolute value) in DNA methylation percent of
0.25 in LINE-1 per IQR (19 μg/g) of patella lead [68] to
0.75 in Alu per log ng/g lipid increase of α-Chlordane
concentrations [100]. Among studies reporting differences
in the relative scale, the corresponding associations ranged
from a relative change of 14% comparing tertiles 3 to 1 of
lead [69] to 75% comparing participants above and below
the median cadmium levels [19]. Some of the retrieved
studies reported dose-responses using flexible approaches
(that is, quantile categories or nonparametric splines) and
mostly showed fairly monotonic relationships of DNA
methylation with cadmium [55], lead [68,69], and POPs
[20,98-100], which add further significance to the findings.
Overall, the temporality of the reported associations
cannot be evaluated in this systematic review given the
low number of prospective studies. Among the four stud-
ies with originally prospective designs [19,55,68,101], all of
them reported cross-sectional analyses with samples for
DNA methylation and exposure status determination col-
lected at the same time point. Only two of the prospective
studies [19,101] included repeated measurements and
additionally reported prospective associations of baseline
exposures with DNA methylation in samples collected at
follow-up visits. For cadmium, the cross-sectional associ-
ation with global DNA methylation was statistically signifi-
cant, whereas the prospective association after 10-year
follow-up was not [19]. For PFCs, the associations with
DNA methylation measured at the end of follow-up were
reported not to be different either using biomarkers from
samples collected at enrollment, at the end of follow-up,
or the average of both [101]. The relevant type of exposure
(short term versus long term), latency time, and persist-
ence of the potential epigenetic effects of individual envir-
onmental chemicals in human populations, however, areunknown and may differ by compound. Future longitu-
dinal studies with sufficient repeated measurements over
time, which can enable the evaluation of trends and trajec-
tories of DNA methylation by environmental exposures
levels, are needed.
A major challenge in the evaluation of the association
between environmental chemicals and DNA methyla-
tion was the heterogeneity of adjustment for potential
confounders. For instance, residual confounding by smok-
ing is a typical concern in epidemiologic studies assessing
potential environmental chemical-epigenetic effects, be-
cause tobacco smoke is a major source of chemicals, in-
cluding cadmium, lead, and PAHs, and others [32] that
can have potential epigenetic effects. Most, but not all
[29,53,69,85], of the retrieved articles assessed potential
confounding by smoking. Sex and age are important
sociodemographic factors that must be also considered
as potential confounders, since they have also been re-
lated to differences in DNA methylation [123,124]. Only
three studies did not address confounding by both sex and
age [29,69,119]. In addition to adjustment in regression
models, an alternative strategy to evaluate residual con-
founding is to perform separate analyses in subgroups of
interest, for instance sex or smoking. For cadmium, one
study in Argentinean women [54] the study population
was mostly made of never smokers. For PAH, one study
reported levels of DNA methylation separately for smokers
and non-smokers with no statistically significant differences
[120], and another study reported that all participants were
not current smokers [119]. For POPs, two studies evaluated
findings in smoking status subgroups [99,100], with no sig-
nificant differences in the estimated associations. Four stud-
ies stratified by sex [85,99-101], reporting similar results in
men and women, except a study of mercury in dental pro-
fessional [85] that found a significant association between
hair mercury and SEPP1 hypomethylation only among
males. Eight study populations were made only of adult
men or women [20,29,53,54,68,118-120]. In addition to sex
and smoking, four articles additionally performed subgroup
analysis by candidate polymorphisms [29,30,54,99] mostly
in genes from one-carbon metabolism and exposure-
related pathways (that is, polymorphisms in the Ah re-
ceptor for POPs). In addition to candidate genes, there
is mounting evidence now supporting a role of the gen-
etic variation in cis in determining DNA methylation
status [124,125]. For site-specific methylation, thus, it is
advisable to evaluate whether the observed associations
may be attributed to nearby polymorphisms, which may
be unbalanced by exposure levels by chance. Only one
study reported evaluation of SNP-related clustering of
DNA methylation [53]. Another study incorporated
into the analysis genotypes from SNPs known to deter-
mine DNA methylation in the significant regions of
interest [29].
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ing and methylation assessment methods and tissue-
specific nature of DNA methylation profiles are other
sources of potential biases. It is well established now
that differential tissue-type cell heterogeneity [123,126]
and, for large studies and studies using ‘omics’ technologies
for DNA methylation assessment, evaluation and correc-
tion of potential batch effects [127,128] and background
correction and normalization methods [128,129] are
compelling issues that must be addressed and adequately
reported. Only five studies are reported addressing tissue-
specific cell heterogeneity [19,30,53,68,99]. None of the two
studies using microarrays technologies reported evaluating
potential batch effects [29,53]. Moreover, in the specific case
of microarray technologies, given the large numbers of stat-
istical tests conducted, it is usually required to correct for
multiple comparisons. The only microarray-based study
reporting methods to address multiple comparisons found
no significant associations after controlling of the false posi-
tive rate, something expected given the small sample size of
that study (n = 17) [53]. A total of three [54,69,120] studies
attempted to validate significant regions either by using al-
ternative DNA methylation assays to assess the consistency
of results and/or by conducting functional assays in ex-
perimental models. While there is evidence supporting
that arsenic-related methylation changes are associated
with changes in gene expression [12,130], for other en-
vironmental chemicals, the available epidemiologic evi-
dence is limited. Only one of the reviewed studies for
cadmium [54] had available genome-wide gene expression
measurements. However, the association of changes in
DNA methylation with gene expression was not directly
evaluated for the cadmium-related epigenetic regions.
Epidemiologic studies that include assessments of en-
vironmental chemicals and coupled DNA methylation
and gene expression data are needed.
An emerging issue relates to the inability of sodium bisul-
fite conversion, which is the commonly used method for de-
termination of 5-mC at single-base resolution, to distinguish
5-mC from its oxidative derivative 5-hydroxymethylcytosine
(5-hmC) [131]. It has been reported that 5-hmC is enriched
in intergenic regions, including LINE-1 elements and gene
body regions [132-134]. In studies evaluating the association
of DNA methylation and environmental chemicals using bi-
sulfite conversion based methods for DNA methylation
assessment, residual measurement error by 5-hmC content
is, thus, possible. In one of the reviewed papers [19], which
measured global DNA methylation and hydroxymethylation
in human blood samples (using antibodies specific for 5-
mC and 5-hmC with no cross-specificity), there was a
positive and statistically significant correlation between
both epigenetic marks. Moreover, the direction of the
association of both epigenetic markers with diverse deter-
minants, including some metals, was mostly consistent. Inaddition, there is increasing evidence that 5-hmC could
also play a role in epigenetic regulation of gene expression
and be associated with disease susceptibility [135,136].
The health implications of the relationship between DNA
methylation and hydroxymethylation in differentiated tis-
sues are currently unknown. Advanced technology for
high-throughput parallel sequencing on 5-mC and 5-hmC
profiling across the genome may help to understand the
role of DNA hydroxymethylation and its determinants in
health.
Finally, the role of pre-natal exposure to environmen-
tal chemicals as a determinant of DNA methylation was
out of the scope of this systematic review. Given the
relevance of potential heritability of DNA methylation
changes and post-birth effects of maternal environmen-
tal exposures, we briefly summarize here the epidemio-
logic evidence that reported results on the association
of maternal exposure biomarkers and DNA methylation
in cord blood and was excluded as a result of secondary
exclusion criteria. We identified two studies focusing
on cadmium [26,53] and POPs [22,24], respectively, and
one study investigating lead [25] and PAHs [23], re-
spectively. These studies overall support an association
of pre-natal exposure to environmental chemicals with
epigenetic markers in the offspring, but specific system-
atic reviews are needed.
Conclusions
Increasing evidence supports the role of environmental
chemicals in DNA methylation changes. For cadmium,
lead, and POPs, the evidence could be classified as ‘sug-
gestive but insufficient’ considering some consistency and
evidence of a dose-response relationship across studies,
biological plausibility from experimental findings, and ad-
justment of confounding in epidemiologic studies. How-
ever, we finally concluded that for all the environmental
chemicals evaluated, including cadmium, lead, and POPs,
the current evidence is ‘insufficient’ to support causality
given the heterogeneity among epidemiologic studies in
potential for residual confounding of the associations, dif-
ferences in DNA methylation assessment methods and,
random error, especially because of the limited sample
sizes. Important questions include the need for larger and
longitudinal studies with repeated measures, validation
and replication of findings, the relevance of epigenetic
markers recently gaining attention such as DNA hydro-
xymethylation, the systematic evaluation of the dose-
response relationships, and the investigation of the role
of genetic variation. An emerging area of research is
the role of joint exposures in changing DNA methyla-
tion, although statistical methods to comprehensively
tackle mixtures of compounds are needed. As large co-
horts with available measurements of environmental che-
micals and genome-wide DNA methylation data become
Ruiz-Hernandez et al. Clinical Epigenetics  (2015) 7:55 Page 21 of 24increasingly available, collaborative meta-analyses will
enable to disentangle the role of environmental chemi-
cals as determinants of DNA methylation and, also, to
test the hypothesis that genomic DNA methylation may
mediate chemical-related health effects.
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